Daiichi Sankyo discontinues pactimibe
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Japanese firm is discontinuing its atherosclerosis agent pactimibe following the ACAT inhibitor's failure to show a significant effect in a 534-patient coronary intravascular ultrasound study. The primary endpoint was change from baseline in percent atheroma volume at 18 months. Secondary measures "showed a lower effect of pactimibe on atherosclerosis than standard of care alone and no beneficial effect on the frequency of cardiovascular events," Daiichi says Oct. 26. "As a result, all ongoing clinical studies with pactimibe will be discontinued." The company plans to present an expanded analysis at the American Heart Association's Scientific Sessions Nov. 15...